Baldwin Investment Management LLC Grows Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Baldwin Investment Management LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 5.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,559 shares of the pharmaceutical company's stock after acquiring an additional 668 shares during the quarter. Vertex Pharmaceuticals comprises 0.7% of Baldwin Investment Management LLC's holdings, making the stock its 16th largest holding. Baldwin Investment Management LLC's holdings in Vertex Pharmaceuticals were worth $5,058,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Truvestments Capital LLC grew its holdings in shares of Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after buying an additional 23 shares during the last quarter. Simon Quick Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 1.1% in the fourth quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company's stock worth $900,000 after purchasing an additional 24 shares during the last quarter. Spinnaker Trust lifted its holdings in shares of Vertex Pharmaceuticals by 2.1% in the fourth quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company's stock valued at $497,000 after purchasing an additional 25 shares in the last quarter. Strategic Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 0.6% during the fourth quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company's stock valued at $1,807,000 after buying an additional 25 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its stake in Vertex Pharmaceuticals by 0.7% during the 4th quarter. Moors & Cabot Inc. now owns 3,603 shares of the pharmaceutical company's stock valued at $1,451,000 after acquiring an additional 25 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Down 10.0 %

Vertex Pharmaceuticals stock traded down $50.16 during mid-day trading on Tuesday, hitting $450.03. The company had a trading volume of 7,998,848 shares, compared to its average volume of 1,371,271. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The stock's 50 day moving average price is $491.94 and its two-hundred day moving average price is $466.80. The company has a market capitalization of $115.69 billion, a PE ratio of -204.56, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. During the same quarter in the prior year, the firm earned $4.76 EPS. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $535.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the stock an "overweight" rating in a research report on Tuesday. Royal Bank of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a "sector perform" rating in a research note on Tuesday. Barclays upped their price target on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 11th. Finally, Bank of America lifted their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $515.04.

Insider Activity

In related news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares in the company, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,315 shares of company stock valued at $2,121,012 in the last 90 days. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.